These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 26446698)
1. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698 [TBL] [Abstract][Full Text] [Related]
2. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883 [TBL] [Abstract][Full Text] [Related]
3. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615 [TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142 [TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266 [TBL] [Abstract][Full Text] [Related]
7. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789 [TBL] [Abstract][Full Text] [Related]
8. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829 [TBL] [Abstract][Full Text] [Related]
9. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy. Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173 [TBL] [Abstract][Full Text] [Related]
10. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. Leu L; Baribeault D J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050 [TBL] [Abstract][Full Text] [Related]
11. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605 [TBL] [Abstract][Full Text] [Related]
12. Effect of mannitol on acute kidney injury induced by cisplatin. Bégin AM; Monfette ML; Boudrias-Dalle É; Lavallée E; Samouelian V; Soulières D; Chagnon M; Fournier MA; Letarte N; Adam JP Support Care Cancer; 2021 Apr; 29(4):2083-2091. PubMed ID: 32862356 [TBL] [Abstract][Full Text] [Related]
13. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity. Dana R; Kachhwaha VS Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. El Hamamsy M; Kamal N; Bazan NS; El Haddad M Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970 [TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649 [TBL] [Abstract][Full Text] [Related]
16. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Morgan KP; Buie LW; Savage SW Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599 [TBL] [Abstract][Full Text] [Related]
17. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity. Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773 [TBL] [Abstract][Full Text] [Related]
18. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study. Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717 [TBL] [Abstract][Full Text] [Related]
19. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583 [TBL] [Abstract][Full Text] [Related]
20. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin. Dimery IW; Legha SS J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]